| Literature DB >> 25602602 |
Cornelia C H Wielders1, Anneroos W Boerman1, Barbara Schimmer2, René van den Brom3, Daan W Notermans2, Wim van der Hoek2, Peter M Schneeberger1.
Abstract
BACKGROUND: Little is known about the development of chronic Q fever in occupational risk groups. The aim of this study was to perform long-term follow-up of Coxiella burnetii seropositive veterinarians and investigate the course of IgG phase I and phase II antibodies against C. burnetii antigens and to compare this course with that in patients previously diagnosed with acute Q fever.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25602602 PMCID: PMC4300228 DOI: 10.1371/journal.pone.0116937
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Descriptive characteristics of the study population.
|
|
|
| |
|---|---|---|---|
|
|
| ||
| Median age[ | 50 [44.3–56.0] | 57.5 [50.8–66.0] | |
| Male gender | 55 (72.4) | 52 (53.1) | |
| Symptoms of acute Q fever[ | 3 (4.2)[ | 91 (92.9) | |
| Antibiotic treatment for Q fever >1 month[ | 0 (0.0)[ | 30 (30.6) | |
| IgG phase I titer first sample | <1:1,024 | 57 (75.0) | 76 (77.6) |
| ≥1:1,024 | 19 (25.0) | 22 (22.4) | |
| Province of residence | Noord-Brabant (main epidemic area) | 10 (13.2) | 95 (96.9) |
| Other provinces | 66 (86.8) | 3 (3.1) | |
| Comorbidity | Cardiovascular comorbidity[ | 0 (0.0) | 30 (30.9)[ |
| Rheumatic disease | 1 (1.3) | 9 (9.2) | |
| Inflammatory bowel disease | 1 (1.3) | 0 (0.0) | |
| Diabetes | 2 (2.6) | 9 (9.2) | |
| Chronic kidney failure | 0 (0.0) | 2 (2.0) | |
| Cancer | 1 (1.3) | 9 (9.2) | |
| Use of medication past five years | Immunosuppressive medication | 1 (1.3) | 3 (3.1) |
| Cardiovascular medication[ | 5 (6.6) | 48 (49.0) | |
| EQ-5D score[ | Mobility: problems reported | 4 (5.3) | 31 (32.0)[ |
| Self-care: problems reported | 0 (0.0) | 2 (2.1)[ | |
| Usual activities: problems reported | 9 (12.0)[ | 43 (43.9) | |
| Pain/discomfort: problems reported | 15 (19.7) | 49 (50.0) | |
| Anxiety/depression: problems reported | 8 (10.5) | 21 (21.4) | |
| Median VAS score current health status (range) | 83.5 (45–100)[ | 70 (22–100) | |
| Fatigue measured by NCSI | Score <27 (normal) | 47 (70.1)[ | 31 (33.0)[ |
| Score 27–35 (mildly affected) | 12 (17.9)[ | 14 (14.9)[ | |
| Score >35 (severely affected) | 8 (11.9)[ | 49 (52.1)[ | |
EQ-5D: a standardized instrument for use as a measure of health outcome [19]; IQR: interquartile range; NCSI: Nijmegen Clinical Screening Instrument; VAS: visual analogue scale.
a Age at date of collection follow-up sample.
b Answered with ‘yes’ is shown, ‘no or unknown’ was answered by the remaining participants.
c Pathology of vessels (exclusion of hypertension and varices) or cardiac valves; myocardial infarction, percutaneous coronary intervention, coronary stent, bypass surgery or pacemaker.
d Antihypertensive agents, rhythm and rate control drugs, cholesterol-lowering medicines, anticoagulants, antiplatelet agents.
e EQ-5D score: score 2 and 3 (on a scale of 1–3) defined as problems reported.
f Information missing from five cases.
g Information missing from one case.
h Information missing from three cases.
i Information missing from seven cases.
j Information missing from four cases.
Serological results of IgG phase I and phase II antibody titers in veterinarians (n = 76) and Q fever patients (n = 98) in two samples taken in a three-year time period.
|
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
| <1:32 | NA | NA | 0 (0.0) | 15 (15.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.0) |
| 1:32 | NA | NA | 1 (1.3) | 12 (12.2) | 1 (1.3) | 0 (0.0) | 2 (2.6) | 1 (1.0) |
| 1:64 | NA | NA | 1 (1.3) | 19 (19.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.0) |
| 1:128 | NA | NA | 9 (11.8) | 21 (21.4) | 3 (3.9) | 0 (0.0) | 4 (5.3) | 1 (1.0) |
| 1:256 | 38 (50.0) | 40 (40.8) | 18 (23.7) | 11 (11.2) | 19 (25.0) | 0 (0.0) | 16 (21.1) | 16 (16.3) |
| 1:512 | 19 (25.0) | 36 (36.7) | 20 (26.3) | 8 (8.2) | 37 (48.7) | 4 (4.1) | 31 (40.8) | 13 (13.3) |
| 1:1,024 | 14 (18.4) | 13 (13.3) | 21 (27.6) | 6 (6.1) | 10 (13.2) | 18 (18.4) | 18 (23.7) | 23 (23.5) |
| 1:2,048 | 4 (5.3) | 4 (4.1) | 5 (6.6) | 3 (3.1) | 4 (5.3) | 25 (25.5) | 4 (5.3) | 24 (24.5) |
| 1:4,096 | 1 (1.3)[ | 2 (2.0) | 1 (1.3) | 1 (1.0) | 2 (2.6)[ | 30 (30.6) | 1 (1.3) | 14 (14.3) |
| 1:8,192 | 0 (0.0) | 3 (3.1) | 0 (0.0) | 2 (2.0)[ | 0 (0.0) | 21 (21.4)[ | 0 (0.0) | 3 (3.1)[ |
| 1:16,384 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.0) |
|
| 0.419 | <0.001 | <0.001 | <0.001 | ||||
NA: not applicable.
a First serum sample: veterinarians in 2009 or 2010; patients in 2008 or 2009 (twelve months after acute Q fever diagnosis in 2007 or 2008).
b Follow-up sample: veterinarians in 2013 (three to four years after first sample); patients in 2011 or 2012 (four years after acute Q fever diagnosis in 2007 or 2008).
c P-value calculated with Mann-Whitney U test by comparing antibody titers between veterinarians and Q fever patients.
d One sample with a result of >1:2,048.
e Including one sample with a result of >1:4,096.
f Including 17 samples with a result of >1:4,096.
g Including two samples with a result of >1:4096.
Course of IgG phase I and phase II antibody titers (increase, constant, decrease) in veterinarians (n = 76) and Q fever patients (n = 98) in two samples taken in a three-year time period.[a]
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
|
| ||
|
|
|
|
| ||
| Increase | Total increase | 28 (36.8) | 6 (6.1) | 23 (30.3) | 6 (6.1) |
| 2-fold | 21 (27.6) | 4 (4.1) | 17 (22.4) | 4 (4.1) | |
| 4-fold | 7 (9.2) | 0 (0.0) | 6 (7.9) | 0 (0.0) | |
| 8-fold | 0 (0.0) | 1 (1.0) | 0 (0.0) | 0 (0.0) | |
| ≥16-fold | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Undetermined[ | 0 (0.0) | 1 (1.0) | 0 (0.0) | 2 (2.0) | |
| Constant | 23 (30.3) | 10 (10.2) | 30 (39.5) | 16 (16.3) | |
| Decrease | Total decrease | 24 (31.6) | 82 (83.7) | 23 (30.2) | 75 (76.5) |
| 2-fold | 18 (23.7) | 17 (17.3) | 19 (25.0) | 27 (27.6) | |
| 4-fold | 5 (6.6) | 29 (29.6) | 2 (2.6) | 17 (17.3) | |
| 8-fold | 1 (1.3) | 12 (12.2) | 1 (1.3) | 10 (10.2) | |
| ≥16-fold | 0 (0.0) | 24 (24.5) | 0 (0.0) | 7 (7.1) | |
| Undetermined[ | 0 (0.0) | 0 (0.0) | 1 (1.3) | 14 (14.3) | |
| No end titration, not specified[ | 1 (1.3) | 0 (0.0) | 0 (0.0) | 1 (1.0) | |
a First serum sample: veterinarians in 2009 or 2010; patients in 2008 or 2009 (twelve months after acute Q fever diagnosis in 2007 or 2008). Follow-up sample: veterinarians in 2013 (three to four years after first sample); patients in 2011 or 2012 (four years after acute Q fever diagnosis in 2007 or 2008).
b Because some samples did not have and end titration (e.g., >1:4,096), the number of decreased dilutions could not be established.
Figure 1Boxplot of IgG phase I antibodies in two samples obtained from veterinarians (n = 78) and Q fever patients (n = 98) in a three-year time period.
The horizontal dark lines within the boxes represent the median antibody titer, the lower and upper boundaries of the boxes represent the 25th and 75th percentiles, and the T-bars represent the 2.5th and 97.5th percentiles. Outliers are indicated with dots, extreme outliers (more than three times the height of the box) with asterisks. First serum sample: veterinarians in 2009 or 2010; patients in 2008 or 2009 (twelve months after acute Q fever diagnosis in 2007 or 2008). Follow-up sample: veterinarians in 2013 (three to four years after first sample); patients in 2011 or 2012 (four years after acute Q fever diagnosis in 2007 or 2008). When no end titration available: >1:2,048 categorized as 1:4,096, and >1:4,096 categorized as 1:8,912.